By IDSE News Staff
Cefiderocol (Fetroja, Shionogi) was efficacious and well tolerated in the treatment of serious gram-negative bacterial infections in real-world settings among a seriously ill patient population, many of whom required intensive care, according to new data presented at IDWeek 2024, in Los Angeles (poster 1475).
The data came from the PROVE study, an international, multicenter, retrospective medical chart review study, to examine the patient characteristics and clinical outcomes